Summary:The aim of the study was to correlate busulphan (BU) levels of thalassaemia patients with outcome of allogeneic transplant. BU levels were measured by gas chromatography mass fragmentography. All patients received a standardised dose of BU 16 mg/kg, and cyclophosphamide 150 or 200 mg/kg. For area-under-thecurve analysis (AUC), blood samples were obtained at 0, 1, 2, 3, 4 and 6 h after the first and fifth dose for all patients, and additional levels were measured after ninth and/or 13th dose in most patients. Outcome parameters examined included veno-occlusive disease of liver (VOD), idiopathic interstitial pneumonitis, chimerism, and day 90 survival. Twenty consecutive thalassaemia patients who underwent haematopoietic stem cell transplantation were studied. The median age at transplant was 11.2 years (range 3-21 years). Mean BU AUC levels were correlated with age at transplant (r ؍ 0.58, P ؍ 0.007). Nine patients developed VOD and six had mixed chimerism, but these did not correlate with mean BU AUC level. Four patients died before day 50 from VOD and interstitial pneumonitis. Patients with BU AUC levels greater than the median (908 mol ؋ min/l) had significantly lower probability of survival at day 90 (60%), whereas patients with BU AUC level less than the median all survived beyond day 90. No patient had graft rejection. In conclusion, a high BU AUC level was associated with a higher treatment-related mortality in thalassaemia patients after transplant. Keywords: busulphan; early mortality; thalassaemia Thalassaemia major is the most common non-malignant disease being treated by haematopoietic stem cell transplant. Conditioning with busulphan (BU) and cyclophosphamide has been adopted by most centres. The long-term disease-free survival has been reported to be in the range of 60 to 90% depending on risk factors which include age, hepatomegaly, iron chelation and hepatic fibrosis. 1 Early results have shown a high incidence of treatment-related mortality (TRM) in the high risk patients. Reduction of intensity of conditioning reduces the TRM but at the expense of higher rejection rate. 2 It has been suggested that use of BU in conditioning is associated with a higher incidence of veno-occlusive disease (VOD) and interstitial pneumonitis. BU kinetics based on area-under-the-curve or concentration at steady state has been studied to correlate with treatment complications, graft rejection, relapse of leukaemia and transplant-related mortality. [3][4][5][6] We analysed the plasma BU levels in 20 thalassaemia patients and the relationship with outcome parameters.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.